UMN Pharma Inc. today announced that UMN-0501, a novel vaccine being developed by UMN Pharma for pandemic influenza, has been granted orphan drug designation by the Ministry of Health, Labour and Welfare. UMN-0501 is a novel pandemic influenza vaccine manufactured from cell culture using recombinant protein rather than the traditional method that utilizes embryonated-egg culture.

News release PDF file.  (72K)

In order to view this file, you will need to have the following plug-in installed.